During a live event, Moshe C. Ornstein, MD, MA, considered the trial design and outcomes of 2 trials of combination regimens ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Combining ...

The FDA approves a new diagnostic tool enhancing precision treatment for advanced endometrial carcinoma, improving patient ...

Combining lenvatinib (Lenvima) with an immune checkpoint inhibitor in the first-line setting for unresectable hepatocellular carcinoma (HCC) failed to significantly improve survival outcomes in an ...

Please provide your email address to receive an email when new articles are posted on . We do not have a head-to-head comparison of lenvatinib and sorafenib, and we probably never will. We need to ...

Doctor taking notes. The median time to first onset of key adverse reactions was within 5 months of starting lenvatinib-pembrolizumab. The following article features coverage from the International ...

Please provide your email address to receive an email when new articles are posted on . Lenvatinib plus pembrolizumab conferred significantly longer PFS and OS than chemotherapy among women with ...

Lori Wirth, MD: I do want to shift gears, once again, just to touch briefly on what we do when lenvatinib no longer works. For most people, one can have good control of their thyroid cancer over a ...

Merck and Eisai announced disappointing results from 2 clinical trials evaluating pembrolizumab (Keytruda ®) with lenvatinib (Lenvima ®). According to the Companies, the phase 2 LEAP-003 trial ...

Eisai’s multiple receptor tyrosine kinase inhibitor lenvatinib and Merck’s anti–PD-1 therapy pembrolizumab as a combination therapy for patients with renal cell carcinoma received the designation ...

The Food and Drug Administration (FDA) has approved the combination of pembrolizumab (Keytruda, Merck Sharp & Dohme) with lenvatinib (Lenvima, Eisai Inc) for the first-line treatment of adult patients ...

Dublin, April 06, 2023 (GLOBE NEWSWIRE) -- The "Lenvatinib + pembrolizumab Emerging Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering. This ...